A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.
Working under the umbrella of the PsychENCODE Consortium, the mental health research project established in 2015 by the National Institutes of Health, a team of Mount Sinai scientists has uncovered important new insights into the molecular biology of neuropsychiatric disease through two new studies published in a special issue of Science on Friday, May 24.
Generative artificial intelligence (AI), such as GPT-4, can help predict whether an emergency room patient needs to be admitted to the hospital even with only minimal training on a limited number of records, according to investigators at the Icahn School of Medicine at Mount Sinai.
Researchers at the Icahn School of Medicine at Mount Sinai have designed a regenerative medicine therapy to speed up diabetic wound repair. Using tiny fat particles loaded with genetic instructions to calm down inflammation, the treatment was shown to target problem-causing cells and reduce swelling and harmful molecules in mouse models of damaged skin. Details on their findings were published in the May 20 online issue of the Proceedings of the National Academy of Sciences (PNAS).
The Icahn School of Medicine at Mount Sinai Health System is spearheading a collaborative effort to investigate dupilumab as a treatment for children with alopecia areata, a disease that causes extensive hair loss.
Researchers at the Icahn School of Medicine at Mount Sinai have made a significant discovery, identifying genetic connections between inflammatory bowel disease (IBD) and Parkinson’s disease (PD). Published in Genome Medicine on May 13, their study highlights the potential for joint therapeutic strategies to target these two challenging disorders.
Researchers at the Icahn School of Medicine at Mount Sinai have shed valuable light on the complex mechanisms by which a class of psychedelic drugs binds to and activates serotonin receptors to produce potential therapeutic effects in patients with neuropsychiatric disorders such as depression and anxiety.
Twenty years ago today, the East Harlem Health Outreach Partnership (EHHOP) at Mount Sinai opened its doors, creating a new model of community service and patient care. EHHOP, a free student-run, physician-supervised clinic, serves approximately 300 residents of East Harlem every year.
Miriam Merad, MD, PhD, a world-renowned immunologist, has been appointed Dean for Translational Research and Therapeutic Innovation of the Icahn School of Medicine at Mount Sinai. The appointment reaffirms Icahn Mount Sinai’s commitment to pioneering medical progress and catalyzing the rapid advancement of research innovation. Dr. Merad, the Mount Sinai Professor in Cancer Immunology, will also continue to serve as the founding Chair of the Department of Immunology and Immunotherapy, Director of the Marc and Jennifer Lipschultz Precision Immunology Institute, and Director of the Human Immune Monitoring Center.
As Dean, Dr. Merad aims to elevate early clinical trials at Icahn Mount Sinai, streamline the clinical trial process, cultivate a culture of mechanistic clinical trials throughout the campus, and forge stronger partnerships with the pharmaceutical and biotech sectors.
In a scientific breakthrough, Mount Sinai researchers have revealed the biological mechanisms by which a family of proteins known as histone deacetylases (HDACs) activate immune system cells linked to inflammatory bowel disease (IBD) and other inflammatory diseases.
State-of-the-art artificial intelligence systems known as large language models (LLMs) are poor medical coders, according to researchers at the Icahn School of Medicine at Mount Sinai.
RSS